A text message from Joe Rogan just became federal drug policy.
That's the most accurate way to describe what happened when Trump signed an executive order allocating $50 million for psychedelic research. The president literally asked "Can I have some?" during the signing ceremony — with Rogan standing in the Oval Office, presumably nodding approvingly.
We've entered the era where DMT elves have more influence on American healthcare than the American Medical Association.
The executive order fast-tracks research into ibogaine and psilocybin — compounds that have been studied for decades but suddenly became urgent priorities after a podcast host mentioned them enough times. It's policy by proximity, governance by guest list.
Rogan's presence wasn't ceremonial. This is how the influence economy works now — the person who can reach 11 million listeners gets a front-row seat to federal decision-making. The FDA has been methodically evaluating these substances through clinical trials, but apparently the real breakthrough was getting the right person's attention.
The $50 million isn't trivial money. That's funding that could have gone to Alzheimer's research, cancer treatment, or any number of diseases that kill people who can't afford to wait for a podcaster's endorsement.
But here's what nobody wants to acknowledge: this might actually work. Psychedelics show genuine promise for treating depression, PTSD, and addiction. The research is legitimate, even if the path to funding it was ridiculous.
Trump asking "Can I have some?" during a federal policy signing captures something essential about how decisions get made now. It's not about evidence or institutional knowledge — it's about whoever had the president's ear last Tuesday.
— Ish.